OncoTherapy Science (30O) AI Stock Analysis

0 Followers

OncoTherapy Science

(Frankfurt:30O)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-Free Balance SheetZero debt and a 0.0 debt-to-equity ratio reduce fixed financial obligations, while the material increase in equity in 2026 provides a larger capital cushion. This improves resilience and preserves flexibility as the company funds oncology development.

Negative Factors

Declining and Volatile RevenueVolatile and declining revenue makes the commercial base less predictable and weakens operating leverage. Without sustained top-line expansion, the company has less ability to absorb research costs, convert gross-margin gains into earnings, or reduce dependence on capital sources.

OncoTherapy Science (30O) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 37.10M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -7.0
Beta (1Y): 1.18
Revenue Growth: -32.99%
EPS Growth: 24.71%
Country: Germany
Employees: 46
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

OncoTherapy Science Business Overview & Revenue Model

Company Description

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound th...

OncoTherapy Science Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:30O against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:4565	71Outperform	JPY 167.91B	-30.31	-8.51%	―	23.72%	12.48%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JP:4588	51Neutral	JPY 248.42B	-152.49	―	―	1748.97%	35.11%
JP:4587	48Neutral	JPY 138.26B	-47.42	-5.85%	―	14.25%	50.07%
JP:4579	43Neutral	JPY 16.82B	72.18	―	―	31.84%	―
JP:4571	41Neutral	JPY 6.10B	-4.98	-33.61%	―	48.92%	-46.91%

* Healthcare Sector Average

Performance Comparison

DE:30O and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:30O	OncoTherapy Science, Inc.	0.07	-0.04	-35.92%
JP:4587	Peptidream	1065.00	-518.50	-32.74%
JP:4565	Sosei Group Corporation	1813.00	954.00	111.06%
JP:4571	NanoCarrier Co., Ltd.	67.00	-83.00	-55.33%
JP:4579	RaQualia Pharma Inc.	646.00	105.00	19.41%
JP:4588	Oncolys BioPharma, Inc.	8410.00	7342.00	687.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

OncoTherapy Science AI Stock Analysis